FindTrial
Sign In

Stereotactic Radiosurgery for Oligometastatic Cancers in Indian patients

Stereotactic Radiosurgery and Stereotactic Body Radiotherapy for Treatment of Oligometastatic Cancers in Indian patients – A single institution Ambispective Observational Cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/01/039657
Enrollment
261
Registered
2022-01-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

None listed

Sponsors

Amrita Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 or older 2. Willing to provide informed consent 3. Histologically proven malignancy with oligometastatic disease detected on imaging 4. Maximum 3 metastases in one organ and total of 5 metastases and below 5. Life expectancy of more than 6 months

Exclusion criteria

Exclusion criteria: • Pleural effusion • Dominant brain metastasis requiring surgical decompression • Pregnant or lactating women

Design outcomes

Secondary

MeasureTime frame
1. To assess the local control at the site treated with Stereotactic Radiosurgery and stereotactic Body Radiotherapy 2. To assess the progression free survivalTimepoint: 5 years—

Primary

MeasureTime frame
To assess the Overall Survival in patients treated for oligometastatic diseaseTimepoint: 5 years—

Countries

India

Contacts

Public ContactDr Ramakrishna Kamath

Amrita Institute of Medical Sciences

duttadeb07@gmail.com9884234290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026